评论文章:在炎症性肠病中优化生物 (单克隆抗体) 治疗反应
Thanaboon Chaemsupaphan1,2, Rupert W Leong3,4, Niels Vande Casteele5
1Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Mahidol University, Salaya, Thailand.
Alimentary pharmacology & therapeutics
|October 15, 2024
概括
使用治疗药物监测 (TDM) 优化炎症性肠病 (IBD) 的生物疗法可以改善患者的治疗结果. TDM有助于调整药物水平和抗体,以实现超出症状控制的更深度缓解.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 对于炎症性肠病 (IBD) 存在许多治疗选择.
- 标准的IBD治疗剂量往往无法达到治疗目标.
- 优化现有的生物疗法与开发新疗法的同时至关重要.
研究的目的:
- 探索优化对IBD生物疗法反应的策略.
- 突出治疗药物监测 (TDM) 在IBD管理中的作用.
主要方法:
- 对IBD的生物疗法和TDM发表文献进行了广泛的审查.
主要成果:
- 治疗药物监测 (TDM) 测量血清药物度和中和抗体,以提高药物的有效性.
- 对于TNF抑制剂,TDM可以指导剂量优化或免疫调节剂的使用,以减少免疫性和反应丧失.
- 策略包括剂量升级,间隔减少或基于TDM发现的切换疗法.
结论:
- 通过剂量调整优化生物疗法,可能由TDM指导,提高了在IBD中实现临床缓解的可能性.
- 这种方法支持更深层次的缓解水平,在治疗到目标框架内超越仅仅症状控制.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...


